Orchid Pharma Ltd reported a significant 169% year-on-year increase in Profit After Tax for Q1 2024-25, supported by strategic initiatives and market presence, and plans to launch a new drug, ORBLICEF, to combat anti-microbial resistance.
AI Assistant
Orchid Pharma Ltd
2024
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.